A Phase 3 interventional study of VLA1553 in Chikungunya Virus Infection, sponsored by Valneva Austria GmbH. Active, not recruiting at 10 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Valneva Austria GmbH (part of Valneva) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Chikungunya Fever by Valneva — 2 open to participants now, 5 under way, 1 of them phase 3. Chikungunya Fever · Valneva.
Among the 11 studies in Chikungunya Fever by Valneva, this one is one of 2 that started in 2021, is one of 5 in phase 3, and was the 4th registered.
88 studies on the registry are indexed under Chikungunya Fever; 21 are open to participants now.
Browse Chikungunya Fever studies →2 of the 11 studies in Chikungunya Fever by Valneva are open now, in 1 country. Recruiting first, the newest first:
Valneva Austria GmbH · Sites in Brazil
Ages 18+ · Women only · Healthy volunteers
Valneva Austria GmbH · Sites in Brazil
Ages 18–59 · Healthy volunteers
By country, each count listing its studies:
Of the 8 Chikungunya Fever studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2021.
This study's enrollment of 363 is above the median of 263 across 57 interventional studies indexed under Chikungunya Fever.
Median enrollment 304 across the 7 interventional studies, 3,100 across the 4 observational. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Valneva Austria GmbH, one of the names counted as Valneva. Under that name alone:
Valneva Austria GmbH is the lead sponsor of 44 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Chikungunya Fever by Valneva, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).
In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724)
These participants will have annual follow-up visits at Months 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 after immunization. The primary objective of this trial will be to evaluate persistence of antibodies annually from 1 to 10 years after the single immunization with VLA1553. The secondary objective is to evaluate long-term safety 6 months to 2 years after the single immunization with VLA1553.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: VLA1553
Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.
Proportion of Participants With Seroresponse Levels Post-vaccination. (Defined as µPRNT50 ≥150)
Data for Visit 1 - Day 1 are collected from Trial VLA1553-301
Time frame: Year 2
Frequency of Any Serious Adverse Event (SAE)
Time frame: until Year 2
Relatedness of Any Serious Adverse Event (SAE)
Time frame: until Year 2
Immune Response as Measured by CHIKV-specific Neutralizing Antibody Titers Post-vaccination
Time frame: until Year 10
Proportion of Participants With Seroconversion
Time frame: until Year 10
Fold Increase of CHIKV-specific Neutralizing Antibody Titers Post-vaccination as Compared to Baseline (i.e. at Start of Trial VLA1553-301)
Time frame: until Year 10
Proportion of Participants Reaching an at Least 4-fold, 8-fold, 16-fold or 64-fold Increase in CHIKV-specific Neutralizing Antibody Titer Compared to Baseline
Time frame: until Year 10
| Milestone | VLA1553 |
|---|---|
| Started | 363 |
| Completed | 317 |
| Not completed | 46 |
Data for Visit 1 - Day 1 are collected from Trial VLA1553-301
| percentage of participants with SRR | VLA1553: 18 - 64 Years | VLA1553: >=65 Years |
|---|---|---|
| Visit 1 - Day 1 | 0 (0.0 to 0.0) | 0 (0.0 to 0.0) |
| Visit 1 - Year 1 | 99.4 (96.5 to 100.0) | 100 (87.2 to 100.0) |
| Visit 2 - Year 2 | 97 (93.9 to 98.8) | 97.6 (87.4 to 99.9) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Long-term safety (i.e. Serious Adverse Events [SAEs]) was collected 6 months to 2 years after the single immunization with VLA1553.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VLA1553: 18 - 64 Years | 1/310 (0.3%) | 6/310 (1.9%) | — |
| VLA1553: >=65 Years | 0/53 (0%) | 2/53 (3.8%) | — |
| Event | VLA1553: 18 - 64 Years | VLA1553: >=65 Years |
|---|---|---|
| Intracranial aneurysmNervous system disorders | 0/310 | 1/53 |
| Coronary artery diseaseCardiac disorders | 0/310 | 1/53 |
| Gun shot woundInjury, poisoning and procedural complications | 1/310 | 0/53 |
| OverdoseInjury, poisoning and procedural complications | 1/310 | 0/53 |
| Pelvic fractureInjury, poisoning and procedural complications | 1/310 | 0/53 |
| SeizureNervous system disorders | 1/310 | 0/53 |
| Abdominal pain upperGastrointestinal disorders | 1/310 | 0/53 |
| CholecystitisHepatobiliary disorders | 1/310 | 0/53 |
The Whole Sample Population (WSP) contains: * All participants who entered into the VLA1553-303. * Received VLA1553 in trial VLA1553-301. * Had a post-baseline immunogenicity sample available from the VLA1553-301. * Participants need a Visit 1 record on VLA1553-303 to be included in the WS population. This will include all participants who had an informed consent in VLA1553-303 and met all inclusion/exclusion criteria to be enrolled into the trial and had a Visit 1 record in VLA1553-303.
| Age, Customized(years) | VLA1553: 18 - 64 Years | VLA1553: >=65 Years | Total |
|---|---|---|---|
| Mean | 44.1 ± 12.02 | 68.7 ± 3.37 | 47.7 ± 14.15 |
| Sex: Female, Male(Participants) | VLA1553: 18 - 64 Years | VLA1553: >=65 Years | Total |
|---|---|---|---|
| Female | 177 | 30 | 207 |
| Male | 133 | 23 | 156 |
| Ethnicity (NIH/OMB)(Participants) | VLA1553: 18 - 64 Years | VLA1553: >=65 Years | Total |
|---|---|---|---|
| Hispanic or Latino | 40 | 3 | 43 |
| Not Hispanic or Latino | 265 | 49 | 314 |
| Unknown or Not Reported | 5 | 1 | 6 |
| Race/Ethnicity, Customized(Participants) | VLA1553: 18 - 64 Years | VLA1553: >=65 Years | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 6 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 3 |
| Black or African American | 44 | 8 | 52 |
| White | 237 | 43 | 280 |
| Other | 19 | 1 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After trial completion, Valneva may provide access to individual de-identified participant data and related trial documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Trial Report (CTR)) upon request from qualified researchers, and subject to Valneva's review and approval.
Ran from Apr 2021 to primary completion in Mar 2023, 23 months.
Results were first posted in Jul 2026, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chikungunya vaccine